Form 4: Decheng Capital Reduces BeyondSpring Stake

Decheng Capital funds, including a 10% owner and director, reported sales of BeyondSpring Inc. ordinary shares totaling 1,800 units across three transactions in late September 2025.

Summary

• Decheng Capital China Life Sciences USD Fund III, L.P., a 10% owner and director of BeyondSpring Inc., sold a total of 1,800 ordinary shares.
• The sales occurred on September 25, 26, and 29, 2025, through multiple transactions.
• The shares were sold at weighted average prices ranging from $1.64 to $1.76 per share.
• Following these transactions, Decheng Capital China Life Sciences USD Fund III, L.P. beneficially owns 1,845,761 ordinary shares.
• Other affiliated entities, Decheng Capital China Life Sciences USD Fund II, L.P. and Decheng Capital Global Healthcare Fund (Master), LP, continue to beneficially own 1,617,409 and 891,734 ordinary shares, respectively.
• Dr. Xiangmin Cui, manager of the general partners for these funds, is also deemed to beneficially own these securities.

Sentiment

Score: 3

Explanation: The filing reports insider selling by a significant institutional investor and director, which typically signals a lack of confidence or a strategic portfolio adjustment, potentially negatively impacting investor sentiment.

Negatives

• A significant institutional investor and director, Decheng Capital, reduced its stake in BeyondSpring Inc. through multiple sales.
• The sales occurred over three consecutive trading days, which could be interpreted as a systematic reduction of exposure.

Risks

• Potential for negative investor perception due to a major institutional investor and director reducing its holdings, which may signal a lack of confidence.
• The sales could contribute to downward pressure on BeyondSpring Inc.'s stock price.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Sales of ordinary shares by Decheng Capital China Life Sciences USD Fund III, L.P., an entity associated with a 10% owner and director, Dr. Xiangmin Cui.

Stakeholder Impact

• Shareholders may interpret the sales as a negative signal regarding the company's future performance, potentially leading to downward pressure on the stock price.
• Management may face increased scrutiny or questions regarding the company's outlook given the reduction in stake by a major institutional investor and director.

Key Dates

Recommendation

The insider selling by a significant institutional investor and director, Decheng Capital, suggests a potential lack of immediate upside or a strategic portfolio rebalancing. While not necessarily indicative of fundamental deterioration, it introduces a cautionary note for investors, warranting a 'hold' position to observe further developments rather than an outright 'sell' without additional negative catalysts.

Keywords

BeyondSpring Inc., BYSI, Decheng Capital, Insider Selling, Form 4, Share Sale, Institutional Investor, Director Transaction, Equity Disposal